BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

141 related articles for article (PubMed ID: 7646540)

  • 1. Mechanisms of resistance to N-[5-[N-(3,4-dihydro-2-methyl-4- oxoquinazolin-6-ylmethyl)-N-methylamino]-2-thenoyl]-L-glutamic acid (ZD1694), a folate-based thymidylate synthase inhibitor, in the HCT-8 human ileocecal adenocarcinoma cell line.
    Lu K; Yin MB; McGuire JJ; Bonmassar E; Rustum YM
    Biochem Pharmacol; 1995 Jul; 50(3):391-8. PubMed ID: 7646540
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The influence of drug-exposure conditions on the development of resistance to methotrexate or ZD1694 in cultured human leukaemia cells.
    Takemura Y; Kobayashi H; Gibson W; Kimbell R; Miyachi H; Jackman AL
    Int J Cancer; 1996 Mar; 66(1):29-36. PubMed ID: 8608962
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Mechanisms of acquired resistance to the quinazoline thymidylate synthase inhibitor ZD1694 (Tomudex) in one mouse and three human cell lines.
    Jackman AL; Kelland LR; Kimbell R; Brown M; Gibson W; Aherne GW; Hardcastle A; Boyle FT
    Br J Cancer; 1995 May; 71(5):914-24. PubMed ID: 7537518
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Immunoreactive dUMP and TTP pools as an index of thymidylate synthase inhibition; effect of tomudex (ZD1694) and a nonpolyglutamated quinazoline antifolate (CB30900) in L1210 mouse leukaemia cells.
    Aherne GW; Hardcastle A; Raynaud F; Jackman AL
    Biochem Pharmacol; 1996 May; 51(10):1293-301. PubMed ID: 8787544
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Folate-based thymidylate synthase inhibitors as anticancer drugs.
    Jackman AL; Calvert AH
    Ann Oncol; 1995 Nov; 6(9):871-81. PubMed ID: 8624289
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Biological activity and intracellular metabolism of ZD1694 in human leukemia cell lines with different resistance mechanisms to antifolate drugs.
    Takemura Y; Kobayashi H; Miyachi H; Gibson W; Kimbell R; Jackman AL
    Jpn J Cancer Res; 1996 Jul; 87(7):773-80. PubMed ID: 8698629
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Biochemical and biological studies on 2-desamino-2-methylaminopterin, an antifolate the polyglutamates of which are more potent than the monoglutamate against three key enzymes of folate metabolism.
    Rosowsky A; Galivan J; Beardsley GP; Bader H; O'Connor BM; Russello O; Moroson BA; DeYarman MT; Kerwar SS; Freisheim JH
    Cancer Res; 1992 Apr; 52(8):2148-55. PubMed ID: 1313737
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Molecular characterisation of two cell lines selected for resistance to the folate-based thymidylate synthase inhibitor, ZD1694.
    Freemantle SJ; Jackman AL; Kelland LR; Calvert AH; Lunec J
    Br J Cancer; 1995 May; 71(5):925-30. PubMed ID: 7537519
    [TBL] [Abstract][Full Text] [Related]  

  • 9. ICI D1694, a quinazoline antifolate thymidylate synthase inhibitor that is a potent inhibitor of L1210 tumor cell growth in vitro and in vivo: a new agent for clinical study.
    Jackman AL; Taylor GA; Gibson W; Kimbell R; Brown M; Calvert AH; Judson IR; Hughes LR
    Cancer Res; 1991 Oct; 51(20):5579-86. PubMed ID: 1913676
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Quinazoline thymidylate synthase inhibitors: methods for assessing the contribution of polyglutamation to their in vitro activity.
    Jackman AL; Kimbell R; Brown M; Brunton L; Boyle FT
    Anticancer Drug Des; 1995 Oct; 10(7):555-72. PubMed ID: 7495479
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cellular pharmacokinetics of ZD1694 in cultured human leukaemia cells sensitive, or made resistant, to this drug.
    Takemura Y; Gibson W; Kimbell R; Kobayashi H; Miyachi H; Jackman AL
    J Cancer Res Clin Oncol; 1996; 122(2):109-17. PubMed ID: 8576277
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Resistance to tomudex (ZD1694): multifactorial in human breast and colon carcinoma cell lines.
    Drake JC; Allegra CJ; Moran RG; Johnston PG
    Biochem Pharmacol; 1996 May; 51(10):1349-55. PubMed ID: 8787551
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Carrier- and receptor-mediated transport of folate antagonists targeting folate-dependent enzymes: correlates of molecular-structure and biological activity.
    Westerhof GR; Schornagel JH; Kathmann I; Jackman AL; Rosowsky A; Forsch RA; Hynes JB; Boyle FT; Peters GJ; Pinedo HM
    Mol Pharmacol; 1995 Sep; 48(3):459-71. PubMed ID: 7565626
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Kinetic characteristics of ICI D1694: a quinazoline antifolate which inhibits thymidylate synthase.
    Ward WH; Kimbell R; Jackman AL
    Biochem Pharmacol; 1992 May; 43(9):2029-31. PubMed ID: 1596289
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Functional activity of the reduced folate carrier in KB, MA104, and IGROV-I cells expressing folate-binding protein.
    Westerhof GR; Rijnboutt S; Schornagel JH; Pinedo HM; Peters GJ; Jansen G
    Cancer Res; 1995 Sep; 55(17):3795-802. PubMed ID: 7641196
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effects of thymidylate synthase inhibition on thymidine kinase activity and nucleoside transporter expression.
    Pressacco J; Mitrovski B; Erlichman C; Hedley DW
    Cancer Res; 1995 Apr; 55(7):1505-8. PubMed ID: 7882359
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prodrugs of thymidylate synthase inhibitors: potential for antibody directed enzyme prodrug therapy (ADEPT).
    Springer CJ; Bavetsias V; Jackman AL; Boyle FT; Marshall D; Pedley RB; Bisset GM
    Anticancer Drug Des; 1996 Dec; 11(8):625-36. PubMed ID: 9022750
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cross-resistance studies of folylpolyglutamate synthetase-deficient, methotrexate-resistant CCRF-CEM human leukemia sublines.
    McGuire JJ; Heitzman KJ; Haile WH; Russell CA; McCloskey DE; Piper JR
    Leukemia; 1993 Dec; 7(12):1996-2003. PubMed ID: 8255099
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Isolation and characterization of a human ileocecal carcinoma cell line (HCT-8) subclone resistant to fluorodeoxyuridine.
    Zhang ZG; Malmberg M; Yin MB; Slocum HK; Rustum YM
    Biochem Pharmacol; 1993 Mar; 45(5):1157-64. PubMed ID: 8461045
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Novel mechanism(s) of resistance to 5-fluorouracil in human colon cancer (HCT-8) sublines following exposure to two different clinically relevant dose schedules.
    Aschele C; Sobrero A; Faderan MA; Bertino JR
    Cancer Res; 1992 Apr; 52(7):1855-64. PubMed ID: 1532346
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.